Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Tirzepatide: A novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity
Aichler M, Borgmann D, Krumsiek J, Buck A, MacDonald PE, Fox JEM, et al
Mistake 3: eating too late Eating dinner at 9 PM and going to bed at 10:30 PM is a recipe for nighttime nausea, acid reflux, and poor sleep quality
People with liver disease, heavy alcohol intake, heart failure with low oxygen risk, or a history of pancreatitis may need extra caution
Areas Without Adequate Human Evidence Long-term cardiovascular safety Long-term neurological safety Endocrine effects beyond selected hormone measurements Effects on glucose regulation in people Immune responses Allergic reactions Genotoxicity Carcinogenicity Effects in people with cancer or precancerous disease Reproductive and developmental toxicity Pregnancy safety Breastfeeding safety Paediatric exposure Medicine interactions Interaction with hormone or sleep treatments Repeated exposure over months or years Product-Quality Risks Incorrect amino-acid sequence Glu and Asp residue-order errors Wrong terminal groups Incorrect free-base or acetate designation Incorrect peptide quantity Deletion-sequence impurities Incomplete deprotection Residual synthesis reagents Residual solvents Peptide aggregates Degradation during transport or storage Unverified microbiological quality Unverified bacterial-endotoxin control Certificates unrelated to the supplied batch No reports does not mean no risk FDAs adverse-event database search found no Epitalon reports through December 2025
US$ 28.53
US$ 24.10
US$ 27.92
US$ 26.41
US$ 22.50
US$ 20.04
